WOCKPHARMA Wockhardt Ltd Product Launches Announcement 2024 - WOCKHARDT LTD. Press Release WOCKHARDT LTD. awarded high susceptibility breakpoints for Zaynich by US body CLSI for antibiotic treatment of infections caused by resistant pathogens, ongoing Phase 3 study underway, QIDP Status for 6 Anti-bacterial discovery programmes..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Wockhardt Ltd